



control *db/db*). CSA in control and PRAS40 mice (**p<0.01 versus control het; ##p<0.01 versus control *db/db*). (C) *Nppa* and *Nppb* levels (**p<0.01 versus control het; ##p<0.01 versus control *db/db*). (D) Immunoblots of whole heart lysates. Barplots depicting quantitation of Akt phosphorylation. *p<0.05 versus control. (E) Body weight and glucose levels in the indicated groups ***p<0.01 vs hets. (F) Mason-Trichrome staining of liver sections in the indicated groups. Scale bar 150 μ m (G) Blood insulin levels in the indicated groups. ***p<0.01 vs controls. n=5 in each group.

Supporting Figure 4



Supporting Figure 4. (A) TG content in the liver ***p<0.01 versus control chow. (B) Lipid accumulation evidenced by Oil Red O staining. Scale bar 150 μ m.

Supporting Figure 5



Supporting Figure 5. (A) IRS-1 degradation is prevented and Akt phosphorylation is

improved by mTORC1 inhibition with PRAS40. **(B)** Glucose uptake measured is increased in PRAS40 NRCMS. Increase in Glucose Uptake is blocked by Akt inhibition (10µM. Akt V Inhibitor) *p<0.05 vs Control. #p<0.05 vs Control. Error bars indicate means ± sem. **(C)** Immunoblot confirming successful pharmacological Akt inhibition

Supplemental Table 1

18s Forward	5'-CGAGCCGCCTGGATACC-3'
18s Reverse	5'-CATGGCCTCAGTTCGAAAA-3'
ANP Forward	5'-TGGGTCTTGTAGGGCTAAACCT-3'
ANP Reverse	5'-TGAAACTCAAGGGACACCCATCGT-3'
BNP Forward	5'-AATGGCCCAGAGACAGCTTGAA-3'
BNP Reverse	5'-CTTGTGCCCAAAGCAGCTTGAGAT-3'
mPRAS40 Forward	5'-CGGAGAGCACAGACGACGGC-3'
mPRAS40 Reverse	5'-GCACCGACACGGGCAGAGAC-3'
ATP Synthase Beta 1 For	CGTGAGGGCAATGATTATACCAT
ATP Synthase Beta 1 Rev	TCCTGGTCTCTGAAGTATTCAAGCAA
Cytochrome C For	ACCAAATCTCCACGGTCTGTT
Cytochrome C Rev	GGATTCTCCAATACTCCATCAG
Acadm For	GGAAATGATCAACAAAAAAAAGAAGTATTT
Acadm Rev	ATGGCCGCCACATCAGA
Cpt1b For	TCTAGGCAATGCCGTTCAC
Cpt1b Rev	GAGCACATGGGCACCATAC
Acadv1 For	ATCTCTGCCAGCGACTTT
Acadv1 Rev	TTCTGGCTTGTCCAGAACTG
CPT2 For	AGTATCTGCAGCACAGCATCGTA
CPT2 Rev	GGCTTCTGTGCACTGAGGTATCT